预约演示

更新于：2025-03-20

Clindamycin Hydrochloride

盐酸克林霉素

更新于：2025-03-20

概要

基本信息

简介克林霉素于 1966 年首次由林可霉素制成，属于林可酰胺类，通过阻止细菌制造蛋白质起作用。克林霉素是一种抗生素药物，用于治疗多种细菌感染，包括骨髓炎（骨）或关节感染、盆腔炎、链球菌性咽喉炎、肺炎、急性中耳炎（中耳感染）和心内膜炎。它还可用于治疗痤疮和某些耐甲氧西林金黄色葡萄球菌 (MRSA) 的病例。与奎宁合用，可用于治疗疟疾。它可以通过口服、静脉注射以及作为乳膏或凝胶涂抹在皮肤或阴道内使用。

药物类型

小分子化药

别名

7(S)-Chloro-7-deoxylincomycin、7-CDL、C1indamycin Hydrochloride

+ [44]

靶点

50S subunit

作用方式

抑制剂

作用机制

50S subunit抑制剂(50S核糖体亚基抑制剂)

治疗领域

感染口颌疾病耳鼻咽喉疾病+ [4]

在研适应症

急性支气管炎喉炎简单的皮肤和皮肤结构感染(uSSSI)+ [18]

非在研适应症

恶性疟

原研机构-

在研机构

Pfizer Inc.

Pfizer Japan, Inc.

华中药业股份有限公司

非在研机构

Taro Pharmaceuticals U.S.A., Inc.

Sanaria, Inc.

最高研发阶段批准上市

首次获批日期

(1969-10-01),

寻常痤疮厌氧菌感染革兰氏阳性细菌感染+ [1]

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C18H33ClN2O5S

InChIKeyKDLRVYVGXIQJDK-AWPVFWJPSA-N

CAS号18323-44-9

查看全部结构式(2)

关联

175

项与盐酸克林霉素相关的临床试验

NCT06702345

/ Not yet recruitingN/AIIT

Establishing a Clostridioides Difficile Controlled Human Infection Model

This study will investigate in healthy study subjects, the safety and tolerability of a controlled infection with Clostridioides difficile, a gut bacterium that can cause diarrhoea. It is also examined which dosing regimen (with or without antibiotic pretreatment) is required to induce mild symptoms (like diarrhoea) in the majority of study subjects and which microbiota and immunological factors influence this.
To investigate this, healthy adult study subjects will be asked to ingest capsules (pills) containing the Clostridioides bacterium.

开始日期2025-03-01

申办/合作机构

Academisch Ziekenhuis Leiden

[+3]

NCT06841003

/ Not yet recruiting临床3期

Laparoscopic Antibiotic Lavage to Prevent Intra-abdominal Abscess Formation in Complicated Appendicitis (ALPACA), a Multicenter Single-blinded RCT.

Appendicitis is one of the most common causes of acute surgical admission. Presently, two types of appendicitis are distinguished: complicated and uncomplicated (phlegmonous). Complicated appendicitis (CA) is defined as gangrenous and/or perforated appendicitis and/or appendicitis with an intra-abdominal or pelvic abscess. Laparoscopic appendectomy has become the preferential mode of surgical treatment. However, development of an intra-abdominal abscess (IAA) remains an important and clinically relevant complication following appendectomy, especially in complicated appendicitis. Although patients with complicated appendicitis receive postoperative intravenous antibiotics, the incidence of IAA remains considerable. The reported incidence of IAA in children and adults with CA is 7.9% - 24%. We recently reported an IAA rate of 12.3% after laparoscopic appendectomy for CA in our own institution. Patients with IAA are readmitted and treated with either antibiotics, image-guided percutaneous drainage, surgical reintervention, or a combination of these treatments. Furthermore, IAA represents a considerable burden for the healthcare system with high readmission rates and reinterventions, prolonged hospital stay, and therefore increased medical costs. Intra operative techniques aiming at more effective infection source control represent a clinically relevant area of investigation. Laparoscopic antibiotic lavage represents a promising concept in order to reduce intra-abdominal abscess formation. Antibiotic lavage is mainly known for the treatment of peritoneal dialysis associated peritonitis. Several studies show promising results of antibiotic peritoneal lavage on the incidence of surgical site infections (SSIs) including IAA in patients with CA. However, these studies were retrospective or conducted in a small number of patients who underwent an open appendectomy while high quality randomized controlled trials have not been performed yet.
The aim of the ALPACA study is to evaluate the effect of laparoscopic antibiotic peritoneal lavage with gentamicin / clindamycin for 3 minutes after appendectomy on the incidence of IAA in patients with CA.

开始日期2025-02-01

申办/合作机构

Stichting Spaarne Gasthuis

[+1]

NCT06494072

/ Recruiting临床4期IIT

Short Versus Standard of Care Antibiotic Duration for Hospitalized Children With Uncomplicated Community-acquired Pneumonia: a Non-inferiority, Randomized Controlled Trial.

The goal of this open label, randomized, non-inferiority clinical trial is to compare the treatment success of a 5 day antibiotic course versus a standard antibiotic course (usually 7-14 days of antibiotics) in hospitalized children aged 3 months to 18 years, with uncomplicated community acquired pneumonia.
The main questions it aims to answer are:
* Does a 5 day course work as well as standard (longer) courses of antibiotics for treating community acquired pneumonia in children?
* Does a 5 day course cause less antibiotic side effects compared to a standard (longer) course of antibiotics in children with community acquired pneumonia?
Participants will
* be randomly assigned to either receive 5 total days or a total duration decided by the treating physician
* receive a brief follow up questionnaire regarding clinical symptoms, follow up care/antibiotics, and side effects via phone or email at days 5 and 14 from the start of antibiotics
Researchers will compare the experimental group (receiving 5 days duration) with the control group (standard duration) to see if 5 days is as successful as a standard duration.

开始日期2024-08-22

申办/合作机构

Medical College of Wisconsin

100 项与盐酸克林霉素相关的临床结果

登录后查看更多信息

100 项与盐酸克林霉素相关的转化医学

登录后查看更多信息

100 项与盐酸克林霉素相关的专利（医药）

登录后查看更多信息

27,140

项与盐酸克林霉素相关的文献（医药）

2025-12-31·Virulence

Porphyromonas gulae and canine periodontal disease: Current understanding and future directions

Review

作者: Kwack, Kyu Hwan ; Kim, Cheul ; Moon, Ji-Hoi ; Jang, Eun-Young ; Choi, Young-Suk ; Lee, Jae-Hyung

Porphyromonas gulae has emerged as a notable pathogen in canine periodontal disease, akin to Porphyromonas gingivalis in human periodontitis. This review examines the initial isolation, phylogenetic analysis, habitat, host range, relationships with host health status and age, and key pathogenic determinants, including fimbriae, proteases, citrullinating enzyme, and lipopolysaccharide. Control strategies discussed include polyphosphate to disrupt haeme/iron utilization, clindamycin with interferon alpha to reduce bacterial load and enhance the immune response, and a protease inhibitor. Further research is needed to understand strain-level diversity of virulence factors and interactions between P. gulae and other oral bacteria, particularly Fusobacterium nucleatum, a common pathogen in both dogs and humans. The potential for interspecies transmission between dogs and humans warrants further research into these interactions. Extensive in vivo studies across various breeds are crucial to validate the effectiveness of proposed treatment strategies. This review emphasizes P. gulae's role in periodontal health and disease, setting the stage for future research and improved management of canine periodontal disease.

2025-12-31·Future Science OA

A phytotherapeutic approach to hinder the resistance against clindamycin by MRSA: in vitro and in silico studies

Article

作者: Amr, Rula A. ; Carradori, Simone ; Al-Karablieh, Nehaya ; Al-Halaseh, Lidia Kamal ; Al Nsairat, Hamdi ; Al-Samydai, Ali ; Mayyas, Amal ; Zalloum, Waleed A ; Al-Tawalbeh, Deniz ; Al-Mamoori, Farah ; Aburjai, Talal

AIMSThis study investigates the potential effects of essential oils (EOs) in enhancing the efficacy of clindamycin against Methicillin-resistant Staphylococcus aureus (MRSA) using in vitro and computer simulations. The research seeks to identify essential oils that exhibit synergistic activity with clindamycin and determine their potential key active components.MATERIALS AND METHODSEssential oils commonly used in traditional medicine were tested for their antimicrobial activity against MRSA. The minimum inhibitory concentration (MIC) was determined using in vitro microdilution assays. A synergistic test with clindamycin was performed, and molecular docking studies evaluated the interaction between a key compound (trans-cinnamaldehyde) and MRSA protein.RESULTSEOs from Cinnamomum verum, Rosmarinus officinalis, Salvia officinalis, and Thymus vulgaris demonstrated significant inhibitory and synergistic activities against MRSA, standard strain, and human clinical isolates. Gas Chromatography/Mass Spectroscopy identified trans-cinnamaldehyde, eucalyptol, and thymol as prominent antibacterial compounds. Molecular docking studies confirmed trans-cinnamaldehyde's strong binding to MRSA's AgrA protein, elucidating its enhanced efficacy.CONCLUSIONThe study underscores the potential of plant-based therapies to augment the effectiveness of conventional antibiotics like clindamycin in combating MRSA and addressing antibiotic resistance by integrating traditional plant remedies with modern medical approaches.

2025-05-01·Microbial Pathogenesis

Phenotypic and genomic analysis of Enterococcus avium MC09 pathogenicity isolated from Scylla spp. (mud crab) in a Thai market

Article

作者: Surachat, Komwit ; Singkhamanan, Kamonnut ; Pomwised, Rattanaruji ; Yaikhan, Thunchanok ; Chaichana, Nattarika ; Suwannasin, Sirikan ; Wonglapsuwan, Monwadee

Enterococcus avium is a Gram-positive pathogenic bacterium classified under the Enterococcaceae family. E. avium has been isolated from diverse environmental sources, raising concerns about its potential role in the spread of antibiotic resistance. E. avium MC09, isolated from a mud crab in a Thai market, was analyzed for its antibiotic resistance and pathogenic potential in this study. The isolation of E. avium from mud crab is significant as it highlights the potential role of seafood as a reservoir for antibiotic-resistant bacteria, which may pose risks to public health throughout the food chain. Antibiotic susceptibility testing using the Kirby-Bauer disk diffusion method revealed that E. avium MC09 is resistant to clindamycin, erythromycin, streptomycin, and tetracycline, and exhibits alpha hemolysis on blood agar, indicating its potential virulence. Genomic DNA was extracted and sequenced using the Oxford Nanopore Technologies (ONT) platform, revealing the presence of resistance genes for macrolides (ermB) and tetracyclines (tetL and tetM). Furthermore, several virulence-associated genes were detected, such as srtC, ecbA, efaA, dltA, cpsA/uppS, cpsB/cdsA, cylR2, icps4I, cpsY, epsE, vctC, mgtB, ndk, lisR, and lgt suggesting a pathogenic potential. Additionally, the study identified several insertion sequences (ISs), including (IS1216, IS1216E, IS1216V, IS6770, ISEfa7, ISEfa8, and ISS1W which are commonly found in pathogenic Enterococcus strains. The presence of these IS elements further emphasizes the strain's potential for virulence and genetic adaptability. This study provides comprehensive insights into both the phenotypic and genotypic characteristics of E. avium MC09, highlighting its antimicrobial resistance and pathogenic mechanisms, and underlines the importance of monitoring antibiotic resistance in seafood-associated bacteria.

101

项与盐酸克林霉素相关的新闻（医药）

2025-03-10

·drugs

Treating Male Partners Reduces Recurrence in Bacterial Vaginosis

MONDAY, March 10, 2025 -- Treating male partners in addition to women with bacterial vaginosis results in a lower rate of recurrence than treating only women, according to a study published in the March 6 issue of the New England Journal of Medicine . Lenka A. Vodstrcil, Ph.D., from the Melbourne Sexual Health Centre at Monash University in Australia, and colleagues conducted an open-label, randomized controlled trial involving monogamous heterosexual couples in which the woman had bacterial vaginosis. In the partner-treatment group, the woman received first-line recommended antimicrobial agents and the male partner received oral and topical antimicrobial treatment (metronidazole 400-mg tablets and 2 percent clindamycin cream applied to penile skin, both twice daily for seven days), while in the control group, the woman received first-line treatment and the male partner received no treatment. Eighty-one and 83 couples were assigned to the partner-treatment and control groups, respectively. After 150 couples had completed the 12-week follow-up period, the trial was stopped by the data and safety monitoring board because treatment of the woman only was inferior to treatment of both the woman and her male partner. The researchers found that recurrence occurred in 35 and 63 percent of women in the partner-treatment and control groups, respectively, in the modified intention-to-treat population (recurrence rate, 1.6 and 4.2 per person-year, respectively). Adverse events included nausea, headache, and metallic taste in treated men. "Our trial showed that treating male partners with a week of oral metronidazole and topical clindamycin, together with treatment of women, resulted in a lower rate of recurrence of bacterial vaginosis within 12 weeks than treatment of the woman alone," the authors write.

临床结果临床3期合格传染病产品微生物疗法

2025-02-20

·国家药品监督管理局

国家药监局公布药品说明书适老化及无障碍改革试点名单（第四批）

根据《国家药监局关于发布药品说明书适老化及无障碍改革试点工作方案的公告》（2023年第142号），省级药品监管部门和国家药监局药品审评中心报送了参与试点的药品上市许可持有人和药品名单（第四批），现予公布。序号药品名称药品上市许可持有人1替格瑞洛片华润双鹤药业股份有限公司2非布司他片华润双鹤药业股份有限公司3盐酸贝那普利片北京诺华制药有限公司4甲钴胺片辽宁亿帆药业有限公司5布洛伪麻片辽宁亿帆药业有限公司6盐酸奈福泮片辽宁亿帆药业有限公司7红霉素肠溶片辽宁亿帆药业有限公司8乙酰螺旋霉素片辽宁亿帆药业有限公司9双氯芬酸钠肠溶片辽宁亿帆药业有限公司10益肝灵片辽宁亿帆药业有限公司11复方磺胺甲噁唑片辽宁亿帆药业有限公司12盐酸莫雷西嗪片辽宁亿帆药业有限公司13复方茶碱甲麻黄碱片辽宁亿帆药业有限公司14复方妥英麻黄茶碱片辽宁亿帆药业有限公司15伤科跌打片辽宁亿帆药业有限公司16清脑降压片辽宁亿帆药业有限公司17格列本脲片辽宁亿帆药业有限公司18复方阿司匹林片辽宁亿帆药业有限公司19磷酸苯丙哌林胶囊辽宁亿帆药业有限公司20盐酸环丙沙星胶嚢辽宁亿帆药业有限公司21通便灵胶囊辽宁亿帆药业有限公司22氨咖黄敏胶囊朝阳龙城制药有限公司23对乙酰氨基酚片朝阳龙城制药有限公司24复方龙胆碳酸氢钠片朝阳龙城制药有限公司25维D2磷酸氢钙片朝阳龙城制药有限公司26独一味颗粒朝阳龙城制药有限公司27酒石酸美托洛尔片翎耀生物科技（上海）有限公司28利培酮口服溶液翎耀生物科技（上海）有限公司29阿托伐他汀钙片翎耀生物科技（上海）有限公司30利伐沙班片翎耀生物科技（上海）有限公司31氨己烯酸口服溶液用散翎耀生物科技（上海）有限公司32美洛昔康片上海勃林格殷格翰药业有限公司33利奈唑胺片上海迪赛诺医药集团股份有限公司34富马酸丙酚替诺福韦片上海迪赛诺医药集团股份有限公司35齐多拉米双夫定片上海迪赛诺医药集团股份有限公司36扶正化瘀胶囊上海黄海制药有限责任公司37扶正化瘀片上海黄海制药有限责任公司38替米沙坦片上海现代制药股份有限公司39硝苯地平片上海信谊天平药业有限公司40盐酸氨溴索胶囊上海信谊天平药业有限公司41卡托普利片上海信谊天平药业有限公司42辛伐他汀片上海信谊万象药业股份有限公司43甲氨蝶呤片上海上药信谊药厂有限公司44盐酸二甲双胍片上海上药信谊药厂有限公司45雷贝拉唑钠肠溶片上海上药信谊药厂有限公司46瑞舒伐他汀钙片上海上药信谊药厂有限公司47卡培他滨片上海上药信谊药厂有限公司48双氯芬酸钠缓释片上海上药信谊药厂有限公司49盐酸二甲双胍缓释片上海上药信谊药厂有限公司50盐酸胺碘酮片上海上药信谊药厂有限公司51酚氨咖敏片上海上药信谊药厂有限公司52复方甲氧那明胶囊上海上药信谊药厂有限公司53洛索洛芬钠片上海旭东海普药业有限公司54复方卡托普利片上海旭东海普药业有限公司55盐酸氟桂利嗪胶囊上海旭东海普药业有限公司56盐酸安非他酮缓释片（Ⅱ）上海宣泰医药科技股份有限公司57盐酸帕罗西汀肠溶缓释片上海宣泰医药科技股份有限公司58头孢丙烯胶囊上海新亚药业闵行有限公司59头孢拉定胶囊上海新亚药业闵行有限公司60盐酸克林霉素胶囊上海新亚药业闵行有限公司61阿莫西林克拉维酸钾分散片上海新亚药业闵行有限公司62复方磺胺甲噁唑片上海新亚药业闵行有限公司63头孢克肟分散片上海新亚药业闵行有限公司64甲钴胺片上海新亚药业闵行有限公司65单硝酸异山梨酯缓释片上海新亚药业闵行有限公司66丙酸氯倍他索乳膏上海新亚药业闵行有限公司67林可霉素利多卡因凝胶上海新亚药业闵行有限公司68六神丸上海雷允上药业有限公司69关节镇痛巴布膏上海雷允上药业有限公司70通塞脉胶囊江苏康缘阳光药业有限公司71淫羊藿总黄酮胶囊江苏康缘阳光药业有限公司72夜宁胶囊江苏康缘阳光药业有限公司73通塞脉片江苏康缘阳光药业有限公司74参乌益肾片江苏康缘阳光药业有限公司75六味地黄软胶囊江苏康缘阳光药业有限公司76银翘解毒软胶囊江苏康缘阳光药业有限公司77元胡止痛软胶囊江苏康缘阳光药业有限公司78七味通痹口服液江苏康缘阳光药业有限公司79小儿氨酚黄那敏颗粒江苏康缘阳光药业有限公司80非那雄胺片南京海鲸药业股份有限公司81维生素D2软胶囊南京海鲸药业股份有限公司82瑞舒伐他汀钙片南京正大天晴制药有限公司83替格瑞洛片南京正大天晴制药有限公司84枸橼酸托法替布片南京正大天晴制药有限公司85利伐沙班片南京正大天晴制药有限公司86氟唑帕利胶囊江苏恒瑞医药股份有限公司87脯氨酸恒格列净片江苏恒瑞医药股份有限公司88爱普列特片江苏联环药业股份有限公司89苯磺酸左氨氯地平片苏州东瑞制药有限公司90甲磺酸氟马替尼片江苏豪森药业集团有限公司91替米沙坦氢氯噻嗪片常州制药厂有限公司92达格列净片昆山龙灯瑞迪制药有限公司93马来酸氟伏沙明片昆山龙灯瑞迪制药有限公司94二甲双胍恩格列净片（Ⅰ）杭州中美华东制药有限公司95吡格列酮二甲双胍片杭州中美华东制药有限公司96环孢素软胶囊杭州中美华东制药有限公司97克拉霉素片杭州中美华东制药有限公司98他克莫司胶囊杭州中美华东制药有限公司99吗替麦考酚酯分散片杭州中美华东制药有限公司100吗替麦考酚酯片杭州中美华东制药有限公司101吗替麦考酚酯胶囊杭州中美华东制药有限公司102盐酸吡格列酮片杭州中美华东制药有限公司103阿那曲唑片杭州中美华东制药有限公司104吲哚布芬片杭州中美华东制药有限公司105左氧氟沙星片浙江普洛康裕制药有限公司106非布司他片杭州朱养心药业有限公司107利伐沙班片杭州朱养心药业有限公司108硫酸氨基葡萄糖胶囊浙江施强制药有限公司109盐酸伐地那非片浙江施强制药有限公司110替格瑞洛片浙江海正药业股份有限公司111吗替麦考酚酯片浙江海正药业股份有限公司112瑞舒伐他汀钙片瀚晖制药有限公司113左氧氟沙星滴眼液浙江莎普爱思药业股份有限公司114头孢克肟分散片浙江莎普爱思药业股份有限公司115左氧氟沙星片浙江京新药业股份有限公司116瑞舒伐他汀钙片浙江京新药业股份有限公司117苯磺酸氨氯地平片浙江京新药业股份有限公司118阿司匹林肠溶片浙江京新药业股份有限公司119匹伐他汀钙分散片浙江京新药业股份有限公司120阿托伐他汀钙片浙江京新药业股份有限公司121左乙拉西坦片浙江京新药业股份有限公司122盐酸普拉克索片浙江京新药业股份有限公司123盐酸舍曲林片浙江京新药业股份有限公司124复方鱼腥草合剂浙江康恩贝中药有限公司125普瑞巴林胶囊浙江昂利康制药股份有限公司126碳酸镧咀嚼片浙江昂利康制药股份有限公司127利丙双卡因乳膏浙江昂利康制药股份有限公司128磷酸奥司他韦胶囊浙江华海药业股份有限公司129艾司奥美拉唑镁肠溶胶囊浙江华海药业股份有限公司130盐酸度洛西汀肠溶胶囊浙江华海药业股份有限公司131左乙拉西坦缓释片浙江华海药业股份有限公司132培哚普利叔丁胺片浙江华海药业股份有限公司133阿哌沙班片浙江华海药业股份有限公司134非布司他片浙江华海药业股份有限公司135利培酮分散片浙江华海药业股份有限公司136复方鲜竹沥液江西药都樟树制药有限公司137跌打损伤丸江西药都樟树制药有限公司138强力枇杷露江西药都樟树制药有限公司139荷丹片江西沃华济顺医药有限公司140荷丹胶囊江西沃华济顺医药有限公司141硝苯地平控释片江西山香药业有限公司142米拉贝隆缓释片江西山香药业有限公司143奥拉帕利片江西山香药业有限公司144罗沙司他胶囊江西山香药业有限公司145肠炎宁片江西康恩贝中药有限公司146牛黄上清胶囊江西康恩贝中药有限公司147清肝利胆胶囊江西康恩贝中药有限公司148盐酸达泊西汀片江西制药有限责任公司149米诺地尔搽剂山东京卫制药有限公司150乳果糖口服溶液山东京卫制药有限公司151利多卡因氯己定气雾剂山东京卫制药有限公司152丙酸倍氯米松鼻气雾剂山东京卫制药有限公司153水杨酸甲酯气雾剂山东京卫制药有限公司154富马酸酮替芬鼻喷雾剂山东京卫制药有限公司155盐酸索他洛尔片鲁南贝特制药有限公司156阿昔莫司胶囊鲁南贝特制药有限公司157单硝酸异山梨酯分散片鲁南贝特制药有限公司158单硝酸异山梨酯缓释片鲁南贝特制药有限公司159瑞舒伐他汀钙胶囊鲁南贝特制药有限公司160奥美拉唑碳酸氢钠胶囊鲁南贝特制药有限公司161奥美拉唑碳酸氢钠胶囊（Ⅱ）鲁南贝特制药有限公司162非诺贝特酸胆碱缓释胶囊鲁南贝特制药有限公司163恩格列净片山东新时代药业有限公司164枸橼酸托法替布片山东鲁抗医药股份有限公司165盐酸莫西沙星片山东鲁抗医药股份有限公司166替格瑞洛片山东鲁抗医药股份有限公司167头孢氨苄片山东鲁抗医药股份有限公司168阿莫西林胶囊山东鲁抗医药股份有限公司169头孢氨苄胶囊山东鲁抗医药股份有限公司170他达拉非片山东明仁福瑞达制药股份有限公司171盐酸二甲双胍缓释片山东明仁福瑞达制药股份有限公司172氯化钾缓释片宜昌人福药业有限责任公司173磷酸奥司他韦胶囊宜昌人福药业有限责任公司174麦考酚钠肠溶片宜昌人福药业有限责任公司175阿奇霉素干混悬剂宜昌人福药业有限责任公司176阿奇霉素胶囊宜昌人福药业有限责任公司177恩替卡韦片宜昌人福药业有限责任公司178利伐沙班片宜昌人福药业有限责任公司179维生素C片宜昌人福药业有限责任公司180维生素B1片宜昌人福药业有限责任公司181烟酸缓释片宜昌人福药业有限责任公司182塞来昔布胶囊宜昌人福药业有限责任公司183非那雄胺片武汉人福药业有限责任公司184福多司坦片宜昌东阳光长江药业股份有限公司185苯磺酸氨氯地平片宜昌东阳光长江药业股份有限公司186阿奇霉素胶囊宜昌东阳光长江药业股份有限公司187阿奇霉素干混悬剂宜昌东阳光长江药业股份有限公司188磷酸奥司他韦胶囊宜昌东阳光长江药业股份有限公司189磷酸依米他韦胶囊宜昌东阳光长江药业股份有限公司190索磷布韦片宜昌东阳光长江药业股份有限公司191碳酸氢钠片远大医药（中国）有限公司192盐酸曲美他嗪片远大医药（中国）有限公司193替米沙坦氢氯噻嗪片远大医药（中国）有限公司194硫酸羟氯喹片远大医药（中国）有限公司195格列吡嗪片远大医药（中国）有限公司196玻璃酸钠滴眼液湖北远大天天明制药有限公司197妥布霉素滴眼液湖北远大天天明制药有限公司198复方甘草片湖南尔康制药股份有限公司199盐酸特比萘芬喷雾剂湖南及正医药科技有限公司200硝苯地平缓释片（Ⅰ）国药集团广东环球制药有限公司201硝苯地平缓释片（Ⅲ）国药集团广东环球制药有限公司202感冒灵颗粒华润三九医药股份有限公司203硫酸氢氯吡格雷片东莞市阳之康医药有限责任公司204阿奇霉素片东莞市阳之康医药有限责任公司205琥珀酸美托洛尔缓释片东莞市阳之康医药有限责任公司206枸橼酸西地那非片东莞市阳之康医药有限责任公司207阿托伐他汀钙片东莞市阳之康医药有限责任公司208利伐沙班片东莞市阳之康医药有限责任公司209恩他卡朋片东莞市阳之康医药有限责任公司210左氧氟沙星片东莞市阳之康医药有限责任公司211克拉霉素片东莞市阳之康医药有限责任公司212克拉霉素缓释片东莞市阳之康医药有限责任公司213磷酸奥司他韦干混悬剂广东东阳光药业股份有限公司214磷酸奥司他韦胶囊广东东阳光药业股份有限公司215盐酸二甲双胍片广东东阳光药业股份有限公司216瑞舒伐他汀钙片广东东阳光药业股份有限公司217他达拉非片广东东阳光药业股份有限公司218奥氮平片广东东阳光药业股份有限公司219利格列汀二甲双胍片（Ⅰ）广东东阳光药业股份有限公司220利格列汀二甲双胍片（Ⅱ）广东东阳光药业股份有限公司221利格列汀二甲双胍片（Ⅲ）广东东阳光药业股份有限公司222恩替卡韦片广东东阳光药业股份有限公司223利托那韦片广东东阳光药业股份有限公司224氢溴酸加兰他敏口腔崩解片广东东阳光药业股份有限公司225脑心清片广州白云山和记黄埔中药有限公司226绞股蓝总甙片广州白云山和记黄埔中药有限公司227消炎利胆片广州白云山和记黄埔中药有限公司228护肝片广州白云山和记黄埔中药有限公司229痰咳净散广州王老吉药业股份有限公司230痰咳净片广州王老吉药业股份有限公司231跌打榜药酒广东恒诚制药股份有限公司232风油精广东恒诚制药股份有限公司233复方醋酸曲安奈德溶液广东恒诚制药股份有限公司234复方苦参水杨酸散广东恒诚制药股份有限公司235复方鱼腥草片广东恒诚制药股份有限公司236腹可安片广东恒诚制药股份有限公司237感冒伤风咳茶广东恒诚制药股份有限公司238结石通片广东恒诚制药股份有限公司239橘红枇杷片广东恒诚制药股份有限公司240七星茶广东恒诚制药股份有限公司241清热除湿止泻合剂广东恒诚制药股份有限公司242清热除湿止泻颗粒广东恒诚制药股份有限公司243锁仙补肾口服液广东恒诚制药股份有限公司244板蓝根颗粒广东恒诚制药股份有限公司245风寒感冒颗粒广东恒诚制药股份有限公司246风热感冒颗粒广东恒诚制药股份有限公司247复方春砂颗粒广东恒诚制药股份有限公司248感冒清热颗粒广东恒诚制药股份有限公司249感冒止咳颗粒广东恒诚制药股份有限公司250金菊五花茶颗粒广东恒诚制药股份有限公司251小儿七星茶颗粒广东恒诚制药股份有限公司252野菊花颗粒广东恒诚制药股份有限公司253银翘解毒颗粒广东恒诚制药股份有限公司254止咳枇杷颗粒广东恒诚制药股份有限公司255山楂麦曲颗粒广东恒诚制药股份有限公司256生脉颗粒(党参方)广东恒诚制药股份有限公司257寒喘丸广东恒诚制药股份有限公司258藿胆丸广东恒诚制药股份有限公司259大黄䗪虫丸广东恒诚制药股份有限公司260强力枇杷露广东恒诚制药股份有限公司261首乌补肾酒广东恒诚制药股份有限公司262维C银翘片广东恒诚制药股份有限公司263香砂六君丸广东恒诚制药股份有限公司264香砂养胃丸广东恒诚制药股份有限公司265壮腰健肾丸广东恒诚制药股份有限公司266感冒清片广东恒诚制药股份有限公司267巴戟补酒广东恒诚制药股份有限公司268川贝枇杷糖浆广东恒诚制药股份有限公司269胆香鼻炎片广东恒诚制药股份有限公司270复方海蛇酊广东恒诚制药股份有限公司271咳特灵胶囊广东恒诚制药股份有限公司272止咳枇杷糖浆广东恒诚制药股份有限公司273健儿素颗粒广东恒诚制药股份有限公司274健脾颗粒广东恒诚制药股份有限公司275复方南板蓝根颗粒广东恒诚制药股份有限公司276壮腰健肾丸广州白云山陈李济药厂有限公司277昆仙胶囊广州白云山陈李济药厂有限公司278咳喘顺丸广州白云山陈李济药厂有限公司279上清丸广州白云山陈李济药厂有限公司280乌鸡白凤丸广州白云山陈李济药厂有限公司281补脾益肠丸广州白云山陈李济药厂有限公司282舒筋健腰丸广州白云山陈李济药厂有限公司283胃疡宁丸广州白云山陈李济药厂有限公司284妇科养坤丸广州白云山陈李济药厂有限公司285新血宝胶囊广州白云山陈李济药厂有限公司286喉疾灵胶囊广州白云山陈李济药厂有限公司287雷贝拉唑钠肠溶胶囊珠海润都制药股份有限公司288盐酸伐昔洛韦片珠海润都制药股份有限公司289单硝酸异山梨酯缓释胶囊珠海润都制药股份有限公司290双氯芬酸钠缓释胶囊珠海润都制药股份有限公司291雷贝拉唑钠肠溶片珠海润都制药股份有限公司292奥美沙坦酯片珠海润都制药股份有限公司293缬沙坦片珠海润都制药股份有限公司294奥美沙坦酯氢氯噻嗪片珠海润都制药股份有限公司295盐酸伊托必利胶囊珠海润都制药股份有限公司296奥美拉唑肠溶胶囊珠海润都制药股份有限公司297厄贝沙坦胶囊珠海润都制药股份有限公司298吲达帕胺胶囊珠海润都制药股份有限公司299盐酸二甲双胍肠溶胶囊珠海润都制药股份有限公司300阿奇霉素肠溶胶囊珠海润都制药股份有限公司301布洛芬缓释胶囊珠海润都制药股份有限公司302盐酸伊托必利片珠海润都制药股份有限公司303厄贝沙坦片珠海润都制药股份有限公司304缬沙坦氢氯噻嗪片珠海润都制药股份有限公司305茶碱缓释片珠海润都制药股份有限公司306利培酮口服溶液万特制药（海南）有限公司307泊沙康唑肠溶片四川科伦药业股份有限公司308盐酸奥洛他定片四川子仁制药有限公司309磷酸奥司他韦干混悬剂四川子仁制药有限公司310复方酮康唑发用洗剂滇虹药业集团股份有限公司311消食健脾丸红云制药（玉溪）有限公司312七味糖脉舒胶囊昆明龙津药业股份有限公司313生脉饮云南白药集团股份有限公司314银黄口服液云南白药集团股份有限公司315舒列安胶囊云南白药集团股份有限公司316阿奇霉素胶囊云南白药集团股份有限公司317紫楼胃康胶囊云南白药集团股份有限公司318复方牛黄消炎胶囊云南白药集团股份有限公司319诺氟沙星胶囊云南白药集团股份有限公司320田七痛经胶囊云南白药集团股份有限公司321炎可宁胶囊云南白药集团股份有限公司322香砂平胃颗粒云南白药集团股份有限公司323新生化颗粒云南白药集团股份有限公司324田七花叶颗粒云南白药集团股份有限公司325小柴胡颗粒云南白药集团股份有限公司326千紫红颗粒云南白药集团股份有限公司327酚氨咖敏颗粒云南白药集团股份有限公司328小儿解表颗粒云南白药集团股份有限公司329小儿清咽颗粒云南白药集团股份有限公司330小儿感冒颗粒云南白药集团股份有限公司331感冒止咳颗粒云南白药集团股份有限公司332阿司匹林肠溶片云南白药集团股份有限公司333土霉素片云南白药集团股份有限公司334复方南板蓝根片云南白药集团股份有限公司335香砂养胃片云南白药集团股份有限公司336复方岩白菜素片云南白药集团股份有限公司337健胃消食片云南白药集团股份有限公司338克林霉素磷酸酯片云南白药集团股份有限公司339利胆止痛片云南白药集团股份有限公司340消渴灵片云南白药集团股份有限公司341养肝明目片云南白药集团股份有限公司342银杏叶片云南白药集团股份有限公司343云南花粉片云南白药集团股份有限公司344葡萄糖粉剂云南白药集团股份有限公司345生三七散云南白药集团股份有限公司346肿痛凝胶云南白药集团股份有限公司347肿痛搽剂云南白药集团股份有限公司348益脉康片云南白药集团大理药业有限责任公司349益脉康分散片云南白药集团大理药业有限责任公司350清肺抑火片云南白药集团大理药业有限责任公司351通宣理肺片云南白药集团大理药业有限责任公司352泻痢消片云南白药集团大理药业有限责任公司353开胸消食片云南白药集团大理药业有限责任公司354小儿导赤片云南白药集团大理药业有限责任公司355复方黄连素片云南白药集团大理药业有限责任公司356三黄片云南白药集团大理药业有限责任公司357牛黄解毒片云南白药集团大理药业有限责任公司358竹红菌素软膏云南白药集团大理药业有限责任公司359宁心宝胶囊云南白药集团大理药业有限责任公司360六味地黄丸云南白药集团大理药业有限责任公司361妇舒丸云南白药集团大理药业有限责任公司362乳酸菌素片云南白药集团大理药业有限责任公司363氨咖黄敏片云南白药集团大理药业有限责任公司364豆腐果苷片云南白药集团大理药业有限责任公司365硫酸亚铁片云南白药集团大理药业有限责任公司366盐酸小檗碱胶囊云南白药集团大理药业有限责任公司367阿咖酚散云南白药集团大理药业有限责任公司368陈香露白露片云南白药集团大理药业有限责任公司369灯盏花素片云南白药集团大理药业有限责任公司370千金藤素片云南白药集团大理药业有限责任公司371盐酸小檗碱片云南白药集团大理药业有限责任公司372维生素C片云南白药集团大理药业有限责任公司373元胡止痛片云南白药集团大理药业有限责任公司374知柏地黄丸云南白药集团大理药业有限责任公司375气血康胶囊云南白药集团文山七花有限责任公司376气血康片云南白药集团文山七花有限责任公司377盐酸氟桂利嗪胶囊西安杨森制药有限公司378和血明目片西安碑林药业股份有限公司379金嗓开音丸西安碑林药业股份有限公司380金嗓利咽丸西安碑林药业股份有限公司381金嗓散结丸西安碑林药业股份有限公司382金嗓开音胶囊西安碑林药业股份有限公司383金嗓利咽胶囊西安碑林药业股份有限公司384金嗓散结胶囊西安碑林药业股份有限公司385金嗓开音片西安碑林药业股份有限公司386金嗓散结颗粒西安碑林药业股份有限公司387金嗓开音颗粒西安碑林药业股份有限公司388甲磺酸普雷福韦片西安葛蓝新通制药有限公司389西黄丸陕西季诺康禾药业有限公司390盐酸多奈哌齐片药云（西安）医药技术有限公司391盐酸托莫西汀口服溶液西安远大科创医药科技有限公司392固肠止泻丸陕西中医药大学制药厂393天麻眩晕宁合剂陕西中医药大学制药厂394消炎退热合剂陕西中医药大学制药厂395四季抗病毒合剂陕西海天制药有限公司396阿娜尔妇洁液陕西海天制药有限公司397枣仁安神颗粒西安万隆制药股份有限公司398固精麦斯哈片西安万隆制药股份有限公司399乌龙散西安万隆制药股份有限公司400保和丸陕西紫光辰济药业有限公司401大山楂丸陕西紫光辰济药业有限公司402济生肾气丸陕西紫光辰济药业有限公司403消积丸陕西紫光辰济药业有限公司404致康胶囊西安千禾药业股份有限公司405痫愈胶囊西安千禾药业股份有限公司406缬沙坦氢氯噻嗪片Novartis Pharma Schweiz AG407奥卡西平片Novartis Pharma Schweiz AG408依伏卡塞片Kyowa Kirin Co., Ltd.409阿帕他胺片Janssen-Cilag International NV410沙格列汀片AstraZeneca AB411沙格列汀二甲双胍缓释片（Ⅰ）AstraZeneca AB412沙格列汀二甲双胍缓释片（Ⅱ）AstraZeneca AB413沙格列汀二甲双胍缓释片（Ⅲ）AstraZeneca AB414拉西地平片GLAXOSMITHKLINE, S.A.415吲哚美辛巴布膏Nipro Pharma Corporation

医药出海

2025-02-13

·PRNewswire

Glenmark Pharmaceuticals Inc., USA launches Clindamycin Phosphate Foam, 1%

MAHWAH, N.J., Feb. 13, 2025 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Clindamycin Phosphate Foam, 1%. Glenmark's Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to the reference listed drug, Evoclin®2 Foam, 1%, of Mylan Pharmaceuticals Inc. According to IQVIA™ sales data for the 12-month period ending December 2024, the Evoclin® Foam, 1% market3 achieved annual sales of approximately $5.8 million*. About Glenmark Pharmaceuticals Ltd. Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. Scrip 100 positions Glenmark amongst the Top 100 biopharmaceutical companies ranked by Pharmaceutical Sales in 2023; while Generics Bulletin places it in the Top 50 Generics and biosimilar companies ranked by sales in 2024. Glenmark's Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 3.3 million lives over the last decade through its CSR interventions. For more information, visit . You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma). References: 1Glenmark's Clindamycin Phosphate Foam, 1% is only approved for the indication(s) listed in Glenmark's approved label. 2All brand names and trademarks are the property of their respective owners. 3Market includes brand and all available therapeutic equivalents. Note: IQVIA data obtained by Glenmark is only available for all approved RLD indications. Glenmark's product is only approved for the indications listed in Glenmark's approved label and is not marketed for all RLD indications. *IQVIA™ National Sales Perspectives: Retail & Non-Retail, December 2024 Logo: SOURCE Glenmark Pharmaceuticals Ltd WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准

100 项与盐酸克林霉素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02132	盐酸克林霉素	G01AA10 J01FF01 D10AF01	DB01190

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
急性支气管炎	日本	Pfizer Japan, Inc.	1970-11-20
简单的皮肤和皮肤结构感染(uSSSI)	日本	Pfizer Japan, Inc.	1970-11-20
中耳炎	日本	Pfizer Japan, Inc.	1970-11-20
咽炎	日本	Pfizer Japan, Inc.	1970-11-20
肺炎	日本	Pfizer Japan, Inc.	1970-11-20
脓皮症	日本	Pfizer Japan, Inc.	1970-11-20
猩红热	日本	Pfizer Japan, Inc.	1970-11-20
继发感染	日本	Pfizer Japan, Inc.	1970-11-20
鼻窦炎	日本	Pfizer Japan, Inc.	1970-11-20
扁桃体炎	日本	Pfizer Japan, Inc.	1970-11-20
腹腔脓肿	美国	Pfizer Inc.	1970-02-22
复杂的皮肤和软组织感染	美国	Pfizer Inc.	1970-02-22
感染	美国	Pfizer Inc.	1970-02-22
腹腔感染	美国	Pfizer Inc.	1970-02-22
生殖道感染	美国	Pfizer Inc.	1970-02-22
呼吸道感染	美国	Pfizer Inc.	1970-02-22
寻常痤疮	-	-	1969-10-01
厌氧菌感染	-	-	1969-10-01
革兰氏阳性细菌感染	-	-	1969-10-01
原虫感染	-	-	1969-10-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
寻常痤疮	药物发现	-	Taro Pharmaceuticals U.S.A., Inc.	2015-01-01
恶性疟	药物发现	加蓬	Sanaria, Inc.	2014-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03261830 (Therapeutic Level I, CTgov)	临床4期	手术伤口感染 \| 肱骨骨折	160	Cefazolin+Clindamycin (Pre-operative Antibiotics)	繭鹹觸製窪襯餘襯憲範(觸齋憲範築窪積鏇鏇選) = 糧夢鹹積願鹹糧鏇憲壓繭蓋衊築選窪網繭蓋築 (遞築餘艱繭餘憲壓襯繭, 願壓餘觸廠簾積簾衊顧 ~ 壓鑰顧齋鏇遞齋襯顧鬱) 更多	-	2024-08-09
				Saline (Saline Placebo)	繭鹹觸製窪襯餘襯憲範(觸齋憲範築窪積鏇鏇選) = 網獵衊鏇壓膚鹽積簾壓繭蓋衊築選窪網繭蓋築 (遞築餘艱繭餘憲壓襯繭, 膚糧鹹範齋餘選鹽鏇顧 ~ 顧鏇衊夢構製築顧範觸) 更多
EHA2024	N/A	恶性疟	1	Artesunate and clindamycin	餘窪壓餘壓製蓋餘觸簾(淵鏇網窪繭範夢襯選繭) = 夢窪範網壓壓膚顧憲顧衊衊簾壓艱艱網鏇網餘 (齋繭製餘顧襯簾膚顧鹹 ) 更多	积极	2024-05-14
				Horse Antithymocyte globulin (ATG) and methylprednisolone	餘窪壓餘壓製蓋餘觸簾(淵鏇網窪繭範夢襯選繭) = 襯鑰選憲衊膚艱糧糧膚衊衊簾壓艱艱網鏇網餘 (齋繭製餘顧襯簾膚顧鹹 ) 更多
NCT03945357 (RINSE, CTgov)	临床3期	腹疝 \| 感染	250	Normal saline (Saline Irrigation)	構繭簾鹽壓餘壓製積齋(願簾廠衊鏇壓選築簾齋) = 顧膚製範鹹觸膚鑰膚遞醖齋構簾壓鬱艱選積齋 (顧醖鹽餘選餘蓋製鑰顧, 襯壓壓選鏇夢簾衊夢壓 ~ 積憲積鏇構廠鹹淵鑰糧) 更多	-	2023-08-24
				Gemcitabine+clindamycin (Antibiotic Irrigation)	構繭簾鹽壓餘壓製積齋(願簾廠衊鏇壓選築簾齋) = 艱鹽鏇積膚淵糧餘顧醖醖齋構簾壓鬱艱選積齋 (顧醖鹽餘選餘蓋製鑰顧, 憲顧憲積淵鹹積鑰製淵 ~ 築餘積鏇遞餘艱繭夢鹽) 更多
NCT02579161 (CTgov)	临床3期	肾结石	98	Fluoroquinolones+cephalosporins+Gentamicin+Ampicillin+Clindamycin (Antibiotics for a 24 Hour Period)	(鹽顧願膚觸製襯淵艱網) = 鏇齋襯鏇鑰糧餘衊衊衊窪鹹範構醖齋蓋膚積齋 (蓋蓋選製醖遞積廠鹽膚, 膚襯構鏇襯網範鏇齋簾 ~ 鹽衊獵憲獵遞築獵夢膚) 更多	-	2023-03-14
				Fluoroquinolones+cephalosporins+Gentamicin+Ampicillin+Clindamycin (Continued Antibiotics)	(鹽顧願膚觸製襯淵艱網) = 廠築選觸憲網簾繭廠願窪鹹範構醖齋蓋膚積齋 (蓋蓋選製醖遞積廠鹽膚, 築蓋積壓願鹽襯鹹構襯 ~ 鹹衊積衊蓋鹽構網積夢) 更多
ARVO2022	N/A	弓形虫病一线	19	Intravitreal Clindamycin	(憲築鹹鬱鏇憲齋夢衊壓) = 鏇鬱壓壓積網構願觸壓夢製選鏇觸願鏇窪繭糧 (觸積餘觸獵鬱觸夢鹽繭 ) 更多	-	2022-05-01
NCT03478163 (CTgov)	临床4期	产后出血 \| 子宫内膜炎	11	antibiotics (Control)	簾顧淵鹽壓顧積構觸觸(觸顧範鏇餘鏇衊糧鹽遞) = 醖艱選醖膚鹽築餘繭簾憲廠夢築鑰憲獵網選範 (膚願蓋憲繭餘壓鬱衊艱, 壓襯廠壓顧醖糧夢遞淵 ~ 積構遞淵鑰膚網壓艱願) 更多	-	2021-10-07
				CeFAZolin 1000 MG+Clindamycin 900 MG in 6 ML Injection (Antibiotics)	簾顧淵鹽壓顧積構觸觸(觸顧範鏇餘鏇衊糧鹽遞) = 糧膚壓遞構夢獵選觸壓憲廠夢築鑰憲獵網選範 (膚願蓋憲繭餘壓鬱衊艱, 膚壓鑰築鑰鹹襯糧獵膚 ~ 淵製鹽遞齋艱製鏇製選) 更多
NCT02730962 (CTgov)	临床2期	代谢综合征 \| 糖尿病前期	12	Fecal Microbiota Transplantation+Neomycin+Clindamycin+Vancomycin (Antibiotics Prior to FMT)	廠鏇構壓遞鏇夢獵遞襯(衊齋願壓獵簾憲窪窪糧) = 餘淵鹹遞獵選膚憲窪窪蓋衊繭窪糧憲範膚獵願 (鹹網襯襯鏇襯鹹夢遞願, 窪壓醖憲簾範選觸廠壓 ~ 範繭糧鏇衊淵觸醖願範) 更多	-	2020-11-20
				Fecal Microbiota Transplantation (Placebo Prior to FMT)	廠鏇構壓遞鏇夢獵遞襯(衊齋願壓獵簾憲窪窪糧) = 獵淵夢糧構夢鏇構壓窪蓋衊繭窪糧憲範膚獵願 (鹹網襯襯鏇襯鹹夢遞願, 膚顧繭構簾餘鑰選簾繭 ~ 膚鹹衊鏇積鏇遞衊顧鏇) 更多
NCT02515305 (CTgov)	临床3期	寻常痤疮	890	Clindamycin+Benzoyl Peroxide Gel (combination) (Test Product)	淵網鏇獵窪築鹽艱糧觸(積鏇齋艱廠鹹醖獵鏇淵) = 鏇範糧觸顧製夢廠鹹顧夢選鹽衊餘製構積艱遞 (餘鬱觸壓繭築鏇選製鏇, 襯襯遞壓壓蓋淵鹽觸簾 ~ 廠顧顧艱壓憲衊夢範齋) 更多	-	2020-11-16
				Clindamycin+Benzoyl Peroxide Gel (Reference) (combination) (Reference Product)	淵網鏇獵窪築鹽艱糧觸(積鏇齋艱廠鹹醖獵鏇淵) = 觸繭願衊壓構淵廠構製夢選鹽衊餘製構積艱遞 (餘鬱觸壓繭築鏇選製鏇, 壓製築鹽鑰獵顧獵憲獵 ~ 遞夢蓋網壓蓋繭夢憲遞) 更多
NCT03522441 (CTgov)	临床3期	寻常痤疮	1,125	Clindamycin 1% Gel (Clindamycin 1% Gel (Akorn Pharmaceuticals))	壓鹽積淵遞選構夢衊膚(獵鏇顧鏇簾衊鏇範淵衊) = 網顧顧顧壓膚蓋餘淵繭壓壓製壓構艱觸範夢遞 (製壓構繭膚糧齋鏇衊廠, 選糧鹹鑰鹹餘積觸鹽鹹 ~ 遞鏇蓋衊醖積願衊膚壓) 更多	-	2020-10-05
				Clindamycin 1% Gel (Clindamycin 1% Gel (Greenstone LLC))	壓鹽積淵遞選構夢衊膚(獵鏇顧鏇簾衊鏇範淵衊) = 襯獵願遞觸鑰觸憲窪鏇壓壓製壓構艱觸範夢遞 (製壓構繭膚糧齋鏇衊廠, 簾夢鹹齋糧製蓋選獵餘 ~ 觸鹹衊鬱觸鹹蓋餘顧簾) 更多
NCT03374176 (CTgov)	临床3期	糖尿病 \| 牙周袋	42	Amoxicillin 500 mg / Metronidazole 250 mg (AMX-MET)	獵憲構壓淵艱選積築觸(鑰膚鑰築範襯網鏇糧壓) = 餘衊鑰膚醖襯餘膚獵願餘鹹衊鏇願築蓋蓋鬱願 (壓獵繭鹽餘鹽繭鏇窪鏇, 簾構鑰選鹹艱簾製鹹齋 ~ 窪艱齋鑰顧選憲願鹽襯) 更多	-	2020-06-23
				Clindamycin 300 mg (Clindamycin)	獵憲構壓淵艱選積築觸(鑰膚鑰築範襯網鏇糧壓) = 膚齋鏇構襯憲鹹蓋顧簾餘鹹衊鏇願築蓋蓋鬱願 (壓獵繭鹽餘鹽繭鏇窪鏇, 衊廠遞壓繭淵夢遞膚襯 ~ 鏇廠鏇願積築築積廠齋) 更多